RE: Comparison with Peers30 Mar 2023 18:01
All this is historic and will be in accounts for that year. £9m wrote off from profits as per falsification. What matters now is agreed revised valuation price for medichem and next profit up-dates. As I have said before, they dont want it re-listing yet and want to take into new tax year so that any losses can be realised against future profits. Clean slate in a way and once that is done, then the Company can focus on whats in place now regarding expanding of market share in U.K. & U.S.
Quite happy that this was the correct decision by Bob.